Print

HVTN 112

Evaluating the Safety, Tolerability, and Immunogenicity of a Prime-Boost Regimen of HIV-1 Nef/Tat/Vif, Env pDNA Vaccine Delivered Intramuscularly With Electroporation and HIV-1 rVSV envC Vaccine in Healthy, HIV-Uninfected Adults

Trial Details:

I Ongoing
NIAID; Profectus
rVSV envC ,HIV-1 nef/tat/vif, env pDNA vaccine VSV env C; DNA nef, tat, vif , env
HIV-1 nef/tat/vif, env pDNA vaccine DNA
rVSV envC Viral Vector - Replicating
USA 15
NCT02654080
https://www.clinicaltrials.gov/ct2/show/NCT02654080?term=hvtn+112&rank=1